InspireMD Q1 revenue $3.4M (+122% YoY); voluntary recall of CGuard Prime 135 cm

InspireMD, Inc.

2026-Q1 EPS reported -$0.16 revenue$3,398,000

Net loss $13.7M ($0.16/share) vs $11.2M loss a year ago; operating expenses rose to $14.7M.
GAAP gross profit $0.7M (20.2% margin); adjusted gross profit $1.2M (34.1%) excluding $0.5M impairment charge.
Voluntary recall of CGuard Prime 135 cm; expected costs $700K returns + $650K inventory/remediation.
FDA approved IDE for CGUARDIANS III trial of SwitchGuard NPS; CGuard Prime 80 cm TCAR approval expected H2 2026.
Original CGuard FDA approval anticipated Q3 2026; over 625 cumulative procedures with CGuard Prime since launch.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

InspireMD, Inc. reported first quarter ended March 31, 2026 results: revenue $3.4 million, net income $13.7 million, EPS $0.16 per basic and diluted share.

Period: first quarter ended March 31, 2026
Revenue: $3.4 million
Net income: $13.7 million
EPS: $0.16 per basic and diluted share
Result: reported results

Exact text from the filing

expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- InspireMD Reports First Quarter 2026 Financial Results - Reports total Q1 2026 revenue of $3.4 million, representing year-over-year growth of 122% - - Received IDE approval from FDA to initiate the CGUARDIANS III clinical trial of its SwitchGuard neuro protection system for use in

View on SEC.gov

Browse all earnings releases →

InspireMD, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-021105

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.